

# Impact Of Peak Oxygen Pulse On Patients With Chronic Obstructive Pulmonary Disease

This article was published in the following Dove Press journal:  
International Journal of Chronic Obstructive Pulmonary Disease

Chih-Wei Wu<sup>1,2</sup>  
Po-Chun Hsieh<sup>3,4</sup>  
Mei-Chen Yang<sup>1,2</sup>  
I-Shiang Tzeng<sup>5</sup>  
Yao-Kuang Wu<sup>1,2</sup>  
Chou-Chin Lan<sup>1,2</sup>

<sup>1</sup>Division of Pulmonary Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan; <sup>2</sup>Faculty of Medicine, School of Medicine, Tzu Chi University, Hualien, Taiwan; <sup>3</sup>Department of Chinese Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan; <sup>4</sup>Department of Post-Baccalaureate Chinese Medicine, School of Post-Baccalaureate Chinese Medicine, Tzu Chi University, Hualien, Taiwan; <sup>5</sup>Department of Research, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan

**Introduction:** Patients with chronic obstructive pulmonary disease (COPD) are at an increased risk of cardiovascular comorbidities such as pulmonary hypertension or heart failure. Impaired cardiovascular function often has a significant impact on patients with COPD. Oxygen pulse ( $O_2P$ ) is a surrogate for stroke volume. However, studies regarding  $O_2P$ , health-related quality of life (HRQL), and exercise capacity in patients with COPD are lacking. We aimed to confirm the association between  $O_2P$ , HRQL, exercise capacity, severe exacerbation of COPD, and other parameters in exercise testing.

**Materials and methods:** This study included 79 patients with COPD who underwent lung function testing, a cardiopulmonary exercise test (CPET), Borg Dyspnea Scale evaluation, completion of the St. George's Respiratory Questionnaire, and echocardiography. Cardiovascular comorbidities, COPD-related hospitalizations, and emergency room visits were recorded. We compared these parameters between two groups of patients: those with normal peak  $O_2P$  and those with impaired peak  $O_2P$ . The relationships of peak  $O_2P$  with CPET and lung function were analyzed using simple linear regression.

**Results:** Patients with normal peak  $O_2P$  had higher exercise capacity (peak oxygen uptake and work rate), better HRQL, lower dyspnea score, lower COPD-related hospitalizations, and higher circulatory and ventilator parameters than patients with impaired peak  $O_2P$ . According to a simple linear regression analysis, the anaerobic threshold (AT) and forced expiratory volume in one second (FEV1) showed a significant association with peak  $O_2P$ , and the Pearson correlation coefficients (Pearson's  $r$ ) were 0.756 and 0.461, respectively.

**Conclusion:** Peak  $O_2P$  has a significant impact on exercise capacity, HRQL, dyspnea, COPD-related hospitalization, and circulatory and ventilatory functions in patients with COPD. The AT and FEV1 have strong and moderate associations with peak  $O_2P$ , respectively. Therefore, peak  $O_2P$  is an important indicator of disease severity for patients with COPD.

**Keywords:** cardiopulmonary exercise test, chronic obstructive pulmonary disease, hospitalization, oxygen pulse, health-related quality of life

## Introduction

Chronic obstructive pulmonary disease (COPD) is caused by exposure to noxious particles or gases and characterized by partially reversible airway obstruction with respiratory symptoms including cough, dyspnea, chest tightness, etc.<sup>1</sup> In 2015, COPD was responsible for approximately 3 million deaths worldwide. It is also deemed the fourth leading cause of death in the world and is predicted to rank third by 2020.<sup>1</sup>

With respect to pathophysiology, there is a close interaction between COPD and cardiac function. The principal pathophysiological changes of COPD include airway inflammation, lung emphysema, and pulmonary vascular changes.<sup>2</sup> The obstruction and

Correspondence: Chou-Chin Lan; Yao-Kuang Wu  
Division of Pulmonary Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, No. 289, Jianguo Road, Xindian District, New Taipei City 23142, Taiwan  
Tel +886-2-6628-9779 ext. 2259  
Fax +886-2-6628-9009  
Email bluescopy@yahoo.com.tw; drbfci@yahoo.com.tw

inflammation of COPD cause expiratory flow limitation, air-trapping, and hyperinflation. Airway obstruction and hyperinflation are further associated with impaired left heart diastolic filling.<sup>3</sup> The loss of pulmonary capillaries in emphysematous lungs increases the vascular resistance,<sup>4</sup> and pulmonary vascular remodeling including intimal and smooth muscle hyperplasia leads to pulmonary hypertension.<sup>4</sup>

The cardiopulmonary exercise test (CPET) is regarded as the gold standard for evaluating exercise capacity and both ventilatory and circulatory functions of patients with COPD. Oxygen pulse ( $O_2P$ ) derived from CPET is a non-invasive surrogate for stroke volume (SV).<sup>5,6</sup> Although pulmonary artery catheterization is considered the gold standard of cardiac output measurement in critical care, it is not widely implemented in stable COPD cases due to its invasive nature and possible complications. CPET provides global assessment of integrative exercise responses including cardiovascular, pulmonary, muscular, and cellular oxidative systems, and its application is more widely utilized in patients with COPD. Therefore, studies investigating the parameters of CPET in patients with COPD are important.

It is important to analyze cardiovascular functions in patients with COPD, and CPET is one of the tools used to investigate the circulatory function in these patients.  $O_2P$  reflects SV and is an important parameter in patients with COPD. However, studies on the application of  $O_2P$  in COPD are limited.

Therefore, we aimed to comprehensively analyze the impact of peak  $O_2P$  on COPD in five domains: exercise capacity, circulatory parameters, ventilatory parameters, dyspnea/health-related quality of life (HRQL) score, and severe exacerbation of COPD. Additionally, we studied the association between peak  $O_2P$  and other CPET variables.

## Methods

### Study Cohort

The patients were retrospectively recruited from the outpatient department of the Taipei Tzu Chi Hospital. We collected the clinical data from the medical records. The data included demographic data, laboratory data, data on cardiovascular comorbidities, data from the ABCD assessment tool according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guideline,<sup>1</sup> echocardiography data, and data on the severe exacerbations of COPD. The definition of severe exacerbation was COPD-

related hospitalizations or emergency room (ER) visits. The study was approved by the Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation Institutional Review Board (Protocol Number: 08-XD-046) in accordance with the Declaration of Helsinki and all patients signed informed consent forms.

The inclusion criteria were: (1) a spirometry diagnosis of COPD based on the GOLD criteria,<sup>1</sup> (2) no acute exacerbation of COPD in the last 3 months; and (3) ability to perform exercise on a cycle ergometer independently. The exclusion criteria were: (1) the presence of unstable acute coronary syndrome in the last 3 months or (2) neuromuscular diseases or major surgeries that influenced the exercise test.

### Pulmonary Function Test And Respiratory Muscle Power

Pulmonary function tests by CPFS/D USB<sup>TM</sup> spirometry (Medical Graphics Corporation, St. Paul, MN, USA) were performed according to the American Thoracic Society guidelines.<sup>7</sup> The severity of the airway obstruction was categorized according to GOLD stages.<sup>1</sup> The lung function variables that were recorded included forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and the calculated FEV1/FVC ratio.

Respiratory muscle power was assessed using a direct dial pressure gauge (Respiratory Pressure Meter, Micro Medical Corp., now Vyair Medical, Mettawa, IL, USA) to evaluate the maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP).

### Cardiopulmonary Exercise Test

All patients were evaluated by CPET on an electronically braked cycle ergometer (Corival; Lode B.V., Groningen, The Netherlands) under the supervision of technicians. Some patients who suffered from severe desaturation (pulse oximeter saturation <85%), intolerable dizziness, or chest tightness withdrew from the examination. During CPET, the air was monitored breath-by-breath using the MGC cardiopulmonary diagnostic system (Breeze suite 6.1; Medical Graphics Corporation, St. Paul, MN, USA). CPET variables were measured at an average of 30 s of the breath-by-breath data evaluation. The respiratory exchange ratio (RER) is the ratio between  $CO_2$  production and  $O_2$  consumption during metabolism. It is a surrogate marker of a patient's effort. For the study purposes, qualified exercise required sufficient effort to reach an  $RER \geq 1.1$ .<sup>5</sup> The time of

peak exercise was defined as the achievement of peak oxygen uptake ( $\text{VO}_2$ ).<sup>5</sup> The peak  $\text{O}_2\text{P}$  was defined as the  $\text{O}_2$  P value at the time of peak exercise.

The anaerobic threshold (AT) is defined as the level of oxygen consumption at which point the anaerobic metabolism becomes more dominant than the aerobic metabolism, blood lactate accumulates, and the lactate level rises. The AT was identified using the V-slope method according to a previously reported description.<sup>5</sup> During the exercise test, the respiratory rate, tidal volume, and minute ventilation (VE) were continuously monitored. The ventilatory equivalent (VEQ) is defined as the ratio of VE to carbon dioxide production ( $\text{VCO}_2$ ) at AT. The work efficiency (WE) is the slope of  $\text{VO}_2$  to work rate during exercise. For comprehensive analysis, other variables including heart rate (HR), blood pressure (BP), partial pressure of carbon dioxide at the end of exhaled breath ( $\text{PETCO}_2$ ), and arterial oxygen hemoglobin saturation ( $\text{SpO}_2$ ) were also recorded.

$\text{O}_2\text{P}$  is defined as the ratio of  $\text{VO}_2$  to HR ( $\text{VO}_2/\text{HR}$ ). According to the Fick equation:

$$\begin{aligned}\text{VO}_2 &= \text{cardiac output(CO)} \times \text{oxygen extraction} \\ &= \text{CO} \times [\text{CaO}_2 - \text{CvO}_2] \\ &= \text{HR} \times \text{SV} \times [\text{CaO}_2 - \text{CvO}_2]\end{aligned}$$

Thus,  $\text{O}_2\text{P} = \text{VO}_2/\text{HR} = \text{SV} \times [\text{CaO}_2 - \text{CvO}_2]$ ; where  $\text{CaO}_2$  is arterial oxygen content, and  $\text{CvO}_2$  is venous oxygen content.

Since  $\text{CaO}_2 - \text{CvO}_2$  is assumed to be constant during maximal exercise,<sup>8</sup> peak  $\text{O}_2\text{P}$  is regarded as a non-invasive parameter of SV.<sup>5,6</sup> The normal value of  $\text{O}_2\text{P}$  is 80% of the predicted value. In this study, we analyzed the impact of peak  $\text{O}_2\text{P}$  on COPD cases. We divided the participants into two groups: Group 1 with normal peak  $\text{O}_2\text{P}$  ( $\geq 80\%$  of the predicted value) and Group 2 with impaired peak  $\text{O}_2\text{P}$  ( $< 80\%$  of the predicted value).

## Perceived Dyspnea Measurement And Health-Related Quality Of Life

Borg's category-ratio 10 scale (Borg CR10) was used for rating perceived dyspnea.<sup>9</sup> The Borg CR10 scale is determined at rest and at peak exercise. The scale ranges from 0 to 10, where higher numbers indicate higher degrees of perceived dyspnea.

The St. George's Respiratory Questionnaire (SGRQ) was used to evaluate the health status of COPD.<sup>10</sup> It is a standardized, self-administered questionnaire of 50 items covering four categories: symptoms, physical activities, psychosocial impact, and total scores. The total scores

range from 0 to 100, corresponding to the best and worst quality of life, respectively.

## Echocardiography

The left ventricular ejection fraction (LVEF) and SV were derived from 2D Simpson's biplane analysis. Continuous wave Doppler and the simplified Bernoulli equation were used to estimate the tricuspid regurgitation pressure gradient (TRPG).

## Statistical Analysis

IBM SPSS Statistics software (version 25; IBM Corp., Armonk, NY, USA) was used for data analysis. Continuous data are expressed as the mean  $\pm$  standard deviation or number and percentage, while categorical data are expressed as frequencies and percentages. Chi-squared or Fisher's exact tests (two-tailed) were used to compare categorical variables, independent *t*-tests were used to compare continuous variables with normal distribution, and Wilcoxon rank-sum tests were used for nonparametric statistics. Relationships between continuous variables were assessed using the Pearson correlation coefficient (Pearson's *r*) and simple linear regression analysis. An *r*-value  $> 0.3$  or  $> 0.7$  was considered as a moderate or strong relationship, respectively. A *p*-value  $< 0.05$  was established as the level of significance.

## Results

### Patient Characteristics

The baseline characteristics of all participants are summarized in Table 1. This study enrolled 79 patients with COPD, who were divided into Groups 1 and 2 consisting of 37 and 42 patients, respectively. There were no significant differences detected between the two groups with respect to age, sex, body height, body weight, body mass index, hemoglobin, ABCD assessment tool categorization, smoking history, pharmacologic treatment, cardiovascular comorbidities except hypertension, and echocardiographic parameters. However, the severity of the airway obstruction evaluated under the GOLD criteria was worse in Group 2 than in Group 1 ( $p < 0.01$ ).

### Impact Of Peak $\text{O}_2\text{P}$ On Exercise Capacity In COPD Cases

Exercise capacity between the two groups is shown in Table 2. Patients with impaired peak  $\text{O}_2\text{P}$  had significantly lower exercise capacity as per the assessment of the peak  $\text{VO}_2$  ( $p < 0.001$ ) and peak work rate ( $p < 0.001$ ).

**Table 1** Baseline Characteristics Of The Two Groups

	All (N = 79)	Group 1 (n = 37)	Group 2 (n = 42)	p-value
Age (years)	70 ± 9	71 ± 9	69 ± 9	0.304
Male/female (n)		30/7	38/4	0.331
BH (cm)	162 ± 8	161 ± 8	164 ± 7	0.120
BW (kg)	60 ± 11	59 ± 13	61 ± 10	0.375
BMI (kg/m <sup>2</sup> )	23 ± 4	23 ± 4	24 ± 3	0.702
Hemoglobin (mg/dL)	14 ± 2	14 ± 2	14 ± 2	0.688
GOLD				<0.001
I	3 (4%)	3 (8%)	0 (0%)	
II	30 (38%)	21 (57%)	9 (21%)	
III	39 (49%)	13 (35%)	26 (62%)	
IV	7 (9%)	0 (0%)	7 (17%)	
ABCD assessment				0.562
A	7	4	3	
B	57	27	30	
C	1	1	0	
D	14	5	9	
Smoking				0.108
Non-smoker	10 (13%)	7 (19%)	3 (7%)	
Current smoker	32 (41%)	11 (30%)	21 (50%)	
Ex-smoker	37 (47%)	19 (51%)	18 (43%)	
Pharmacologic Tx				0.688
Nil	1	0	1	
SABD	2	1	1	
LABA+ICS	27	14	13	
LAMA	9	6	3	
LABA+LAMA	10	4	6	
LABA+LAMA+ICS	30	12	18	
CV comorbidities				
CHF	12	6	6	0.811
CAD	3	2	1	0.597
HTN	23	15	8	0.036
Arrhythmia	10	5	5	0.830
Valvular disease	2	1	1	1.000
Echocardiography				
LVEF (%)	67 ± 12	66 ± 14	68 ± 10	0.398
Stroke volume (mL)	65 ± 22	64 ± 22	66 ± 22	0.659
TRPG (mmHg)	28 ± 12	30 ± 14	26 ± 10	0.055

**Note:** Data are presented as mean ± standard deviation or number (percentage).

**Abbreviations:** BH, body height; BW, body weight; BMI, body mass index; COPD, chronic obstructive pulmonary disease; Tx, treatment; SABD, short-acting bronchodilator; LABA, long-acting beta<sub>2</sub>-agonist; ICS, inhaled corticosteroid; LAMA, long-acting antimuscarinic antagonist; CHF, congestive heart failure; CAD, coronary artery disease; CV, cardiovascular; LVEF, left ventricular ejection fraction; TRPG, tricuspid regurgitation pressure gradient; HTN, hypertension.

## Impact Of Peak O<sub>2</sub>P On Circulatory Parameters In COPD Cases

Table 3 shows the circulatory parameters and significant differences can be observed between the two groups. The

**Table 2** Impact Of Peak Oxygen Pulse (O<sub>2</sub>P) On Exercise Capacity

	All (N = 79)	Group 1 (n = 37)	Group 2 (n = 42)	p-value
Peak VO <sub>2</sub> (mL/min)	908.6 ± 273.8	1060.8 ± 268.2	774.5 ± 200.5	<0.001
Peak VO <sub>2</sub> (% predicted)	64.9 ± 17.2	78.9 ± 12.2	52.5 ± 9.8	<0.001
Peak WR (watt)	62.2 ± 26.7	75.1 ± 25.6	50.8 ± 22.2	<0.001
Peak WR (% predicted)	70.3 ± 28.2	89.4 ± 22.9	53.4 ± 20.7	<0.001

**Note:** Data are presented as mean ± standard deviation.

**Abbreviations:** VO<sub>2</sub>, oxygen uptake; WR, work rate.

peak O<sub>2</sub>P was significantly higher in Group 1 ( $8.69 \pm 1.86$  mL/beat) than in Group 2 ( $6.20 \pm 1.36$  mL/beat;  $p < 0.001$ ), while the Group 2 patients had significantly lower AT ( $p = 0.001$ ) and WE ( $p = 0.015$ ). However, no significant differences were detected in HR and mean BP at rest and at peak exercise between the two groups.

## Impact Of Peak O<sub>2</sub>P On Ventilatory Parameters In COPD Cases

The ventilatory parameters are summarized in Table 4. Patients with impaired peak O<sub>2</sub>P (Group 2) showed lower FEV<sub>1</sub> (by numerical value and predicted percentage;  $p = 0.003$  and  $p < 0.001$ , respectively), lower FEV<sub>1</sub>/FVC ratio ( $p < 0.001$ ), lower VE at peak exercise ( $p = 0.001$ ), and higher VEQ ( $p = 0.029$ ) than those with normal peak O<sub>2</sub>P (Group 1). However, there were no significant differences detected in MIP and MEP between the two groups.

## Dyspnea Score And Health-Related Quality Of Life

Table 5 illustrates the dyspnea scores and HRQL of the two groups. There was no significant difference detected in the dyspnea score between the two groups at rest and at peak exercise. The total score of SGRQ of Group 2 was significantly higher than that of Group 1 ( $p = 0.029$ ) with a mean difference of 9.2 points.

## Impact Of Peak O<sub>2</sub>P On Severe Exacerbation Of COPD

There was a clinically relevant impact of peak O<sub>2</sub>P on severe exacerbation of COPD (Table 6). After enrollment, the number of hospitalizations in the following year for Group 2 was higher than for Group 1 (0.57 vs 0.22;  $p = 0.009$ ). Group 2 trended higher for the number of ER visits than Group 1 (0.74

**Table 3** Impact Of Peak Oxygen Pulse (O<sub>2</sub>P) On Circulatory Parameters

	All (N = 79)	Group 1 (n = 37)	Group 2 (n = 42)	p-value
Peak O <sub>2</sub> P (mL/beat)	7.37 ± 2.03	8.69 ± 1.86	6.20 ± 1.36	<0.001
Peak O <sub>2</sub> P (% predicted)	78.8 ± 19.0	96.0 ± 10.4	63.6 ± 9.4	<0.001
AT (mL/min)	615.9 ± 139.4	667.7 ± 134.0	568.0 ± 128.1	0.001
AT (% predicted)	44.2 ± 10.0	50.4 ± 9.3	38.5 ± 6.8	<0.001
WE (mL/min/watt)	8.2 ± 1.9	8.7 ± 1.9	7.7 ± 1.7	0.015
MBP rest (mmHg)	89.5 ± 11.1	87.2 ± 11.8	91.4 ± 10.0	0.088
MBP peak (mmHg)	107.6 ± 15.1	107.5 ± 15.8	107.7 ± 14.7	0.953
HR rest (beats/min)	86.5 ± 12.9	85.1 ± 13.2	87.8 ± 12.6	0.363
HR peak (beats/min)	123.6 ± 16.6	122.4 ± 17.0	124.7 ± 16.4	0.532

**Note:** Data are presented as mean ± standard deviation.

**Abbreviations:** AT, anaerobic threshold; WE, work efficiency; MBP, mean blood pressure; HR, heart rate.

vs 0.38;  $p = 0.112$ ), but the difference did not reach the level of significance.

## Relationship Between AT And FEV1 With Peak O<sub>2</sub>P

Figure 1 reveals a significant correlation between AT and peak O<sub>2</sub>P ( $p < 0.001$ ), showing a strong relationship (Pearson's  $r = 0.756$ ). Figure 2 illustrates a significant correlation between FEV1 and peak O<sub>2</sub>P ( $p < 0.001$ ), showing a moderate relationship (Pearson's  $r = 0.461$ ).

## Discussion

This study reported some important findings. Patients with impaired peak O<sub>2</sub>P demonstrated poor exercise capacity, circulatory condition (such as AT or WE), ventilatory condition, HRQL, and COPD-related hospitalizations. The AT (a circulatory parameter) and FEV1 (a ventilatory parameter) exhibited strong and moderate correlations with peak O<sub>2</sub>P, respectively. Patients with COPD are at an increased risk for cardiovascular dysfunction.<sup>11,12</sup> Since O<sub>2</sub>P is a parameter of SV, it is necessary to understand that

**Table 4** Impact Of Peak Oxygen Pulse (O<sub>2</sub>P) On Ventilatory Parameters

	All (N = 79)	Group 1 (n = 37)	Group 2 (n = 42)	p-value
FVC (L)	2.21 ± 0.69	2.25 ± 0.71	2.18 ± 0.67	0.650
FVC (% predicted)	80.0 ± 19.0	84.2 ± 19.0	76.3 ± 18.4	0.065
FEV1 (L/s)	1.04 ± 0.42	1.18 ± 0.47	0.91 ± 0.32	0.003
FEV1 (% predicted)	47.9 ± 16.0	56.3 ± 15.9	40.5 ± 12.0	<0.001
FEV1/FVC	0.47 ± 0.11	0.53 ± 0.09	0.42 ± 0.10	<0.001
MIP (cm H <sub>2</sub> O)	65.1 ± 26.1	64.8 ± 23.6	65.3 ± 28.4	0.934
MIP (% predicted)	65.8 ± 25.7	67.7 ± 25.4	64.1 ± 26.1	0.538
MEP (cm H <sub>2</sub> O)	109.6 ± 38.1	108.8 ± 27.7	110.3 ± 45.6	0.866
MEP (% predicted)	59.7 ± 20.6	61.7 ± 18.5	57.9 ± 22.3	0.412
VE rest (L/min)	12.1 ± 3.1	12.3 ± 3.1	11.9 ± 3.1	0.574
VE peak (L/min)	32.3 ± 10.3	36.2 ± 9.7	28.8 ± 9.6	0.001
RR rest (breath/min)	19.1 ± 4.6	19.4 ± 4.2	18.9 ± 5.0	0.654
RR peak (breath/min)	32.3 ± 7.4	34.0 ± 6.5	30.8 ± 7.8	0.056
V <sub>T</sub> rest (mL)	652.8 ± 159.4	650.7 ± 146.2	654.6 ± 171.9	0.913
V <sub>T</sub> peak (mL)	1020.0 ± 306.6	1091.9 ± 326.3	956.7 ± 276.8	0.05
VE/VCO <sub>2</sub> at AT	37.0 ± 6.1	35.4 ± 6.4	38.4 ± 5.6	0.029
SpO <sub>2</sub> rest (%)	95.9 ± 2.0	96.2 ± 1.9	95.7 ± 2.1	0.252
SpO <sub>2</sub> peak (%)	92.9 ± 3.6	93.5 ± 3.3	92.4 ± 3.8	0.171
PETCO <sub>2</sub> rest (mmHg)	35.2 ± 5.5	35.6 ± 5.6	35.0 ± 5.4	0.648
PETCO <sub>2</sub> peak (mmHg)	41.0 ± 7.1	41.2 ± 7.9	40.8 ± 6.4	0.778

**Note:** Data are presented as mean ± standard deviation.

**Abbreviations:** FEV1, forced expiratory volume in one second; FVC, forced vital capacity; MIP, maximal inspiratory pressure; MEP, maximal expiratory pressure; VE, minute ventilation; RR, respiratory rate; V<sub>T</sub>, tidal volume; VCO<sub>2</sub>, carbon dioxide production; SpO<sub>2</sub>, arterial oxygen hemoglobin saturation; PETCO<sub>2</sub>, partial pressure of carbon dioxide at the end of exhaled breath.



**Table 5** Impact Of Peak Oxygen Pulse ( $O_2P$ ) On Dyspnea Score And Health-Related Quality Of Life

	All (N = 79)	Group 1 (n = 37)	Group 2 (n = 42)	p-value
Borg CR10, rest (points)	0.47 ± 0.67	0.32 ± 0.63	0.60 ± 0.69	0.073
Borg CR10, peak (points)	5.48 ± 1.66	5.49 ± 1.63	5.48 ± 1.70	0.978
SGRQ, total (points)	36.8 ± 18.6	31.9 ± 15.8	41.1 ± 19.9	0.029
SGRQ, symptom (points)	42.7 ± 22.7	36.8 ± 19.8	47.9 ± 24.0	0.029
SGRQ, activity (points)	51.9 ± 20.0	46.4 ± 18.0	56.6 ± 20.6	0.023
SGRQ, impact (points)	27.2 ± 22.2	23.2 ± 19.9	30.8 ± 23.6	0.129

**Note:** Data are presented as mean ± standard deviation.

**Abbreviations:** Borg CR10, Borg's category-ratio 10 scale; SGRQ, Saint George's Respiratory Questionnaire.

**Table 6** Impact Of Peak Oxygen Pulse ( $O_2P$ ) On The Number Of Hospitalizations And Emergency Room (ER) Visits In The Following Year After Enrollment

	All (N = 79)	Group 1 (n = 37)	Group 2 (n = 42)	p-value
Hospitalizations	0.41 ± 0.968	0.22 ± 0.886	0.57 ± 1.016	0.009 <sup>a</sup>
ER visits	0.57 ± 1.420	0.38 ± 1.361	0.74 ± 1.466	0.112 <sup>a</sup>

**Note:** Data are presented as mean ± standard deviation.

**Abbreviation:** ER, emergency room.


cases with impaired peak  $O_2P$  might be complicated with cardiovascular dysfunction. To the best of our knowledge, this is the first study that comprehensively analyzed the impact of peak  $O_2P$  on exercise capacity, HRQL, severe exacerbation, and circulatory and ventilator parameters in patients with COPD.

The possible mechanisms of cardiac dysfunction in patients with COPD include lung hyperventilation. Prior published reports have demonstrated the close relationship between lung hyperinflation and  $O_2P$ .<sup>13–15</sup> Hyperinflation leads to elevated intrathoracic pressure and results in reduced venous return, which further leads to impaired left ventricular filling and consequently reduced SV. Moreover, pulmonary hypertension leads to increased resistance to right ventricular (RV) contraction and results in RV dilation. The RV dilation further results in compression of the left ventricle (LV) due to ventricular interdependence. Additionally, the increased pulmonary vascular resistance leads to impaired RV systolic function, and therefore, reduced preload of the left heart. A previous study supported the impact of pulmonary hypertension on cardiac function and showed that low peak  $O_2P$  in patients with COPD is associated with pulmonary hypertension.<sup>11</sup> Finally, there is a high incidence of heart failure and COPD overlap.<sup>12</sup> Both conditions share similar risk factors including smoking, aging, and systemic inflammation. Patients with COPD have a 2.57-times higher risk of heart failure as compared to patients without


COPD.<sup>12</sup> The presence of impaired peak  $O_2P$  in patients indicates the comorbidity of heart failure in COPD.

Exercise capacity (peak  $VO_2$ ) is an important issue in COPD. Peak  $VO_2$  is the most important prognostic factor for patients with COPD as well as heart failure.<sup>16</sup> Patients with COPD overlapping with heart failure had poor exercise capacity and higher mortality.<sup>17</sup> Since the comorbidity of heart failure is important in COPD,  $O_2P$  is thus an important parameter in COPD. According to the current study, patients with low peak  $O_2P$  had poor exercise capacity and HRQL.

This is the first study demonstrating that the circulatory parameter AT has a strong relationship with peak  $O_2P$  in



**Figure 1** The simple linear regression between peak oxygen pulse ( $O_2P$ ) and anaerobic threshold (AT). The slant line is calculated using least square regression analysis. ( $p < 0.001$ ;  $R^2 = 0.566$ ; Pearson's  $r = 0.756$ ).



**Figure 2** The simple linear regression between forced expiratory volume in one second (FEV1) and peak oxygen pulse (O<sub>2</sub>P). The slant line is calculated using least square regression analysis. ( $p < 0.001$ ;  $R^2 = 0.202$ ; Pearson's  $r = 0.461$ ).

COPD. AT occurs when the oxygen consumption exceeds the oxygen supply by the cardiovascular system and leads to lactate accumulation and excessive CO<sub>2</sub> production.<sup>18</sup> Therefore, AT indicates the ability of the cardiovascular system to supply oxygen. It has been reported that a lower AT predicts higher mortality in heart failure patients.<sup>19</sup> Since O<sub>2</sub>P is a marker of SV and impaired O<sub>2</sub>P suggests inadequate oxygen delivery, it is conceivable that impaired O<sub>2</sub>P is associated with lower AT.

There are three main impacts of peak O<sub>2</sub>P on ventilatory parameters. First, lung function is correlated with peak O<sub>2</sub>P. In this study, patients with impaired peak O<sub>2</sub>P had lower baseline FEV1. This is the first study demonstrating that FEV1 (a ventilatory parameter) in COPD had a significant correlation with peak O<sub>2</sub>P (a circulatory parameter), and it was a moderate relationship. This could be explained indirectly by the fact that O<sub>2</sub>P is inversely associated with lung hyperinflation<sup>13–15</sup> and lung hyperinflation is inversely associated with the FEV1 level.<sup>20</sup> Second, VE is associated with peak O<sub>2</sub>P; patients with COPD with impaired peak O<sub>2</sub>P showed lower VE at peak exercise. This could be inferred from the fact that O<sub>2</sub>P is inversely associated with hyperinflation,<sup>13–15</sup> and progressive dynamic hyperinflation during exercise leads to lower VE during exercise.<sup>21</sup> Third, VEQ is associated with peak O<sub>2</sub>P, i.e., patients with impaired peak O<sub>2</sub>P have higher VEQ which reflects the patient's ventilatory efficiency. Since patients with impaired peak O<sub>2</sub>P had more severe hyperinflation and poor cardiac function,<sup>22</sup> they had higher VEQ. In previous studies, patients with higher VEQ had higher mortality.<sup>23</sup>

HRQL is important in patients with COPD. It is reported that a poor SGRQ score is associated with increased morbidity and mortality in patients with COPD.<sup>24</sup> Few studies have investigated the correlation between CPET variables and SGRQ. They have shown that in stable patients with COPD, the FEV1, maximal work rate, and breathing reserve are negatively correlated with SGRQ scores, while maximal VO<sub>2</sub> is not significantly associated with SGRQ scores.<sup>25</sup> Although it is intuitive to imagine the association between peak O<sub>2</sub>P and total score of SGRQ, the relationship has not been formally expressed in the literature. A novelty of our study is that the patients with COPD with impaired peak O<sub>2</sub>P had a higher total score of SGRQ than those with normal peak O<sub>2</sub>P, and the mean difference was greater than the minimal clinically important difference (4 points). Impairment of O<sub>2</sub>P in patients with COPD indicates lung hyperinflation and comorbidity with heart failure. Hyperinflation is an important cause of exertional dyspnea in patients with COPD, and it also has a significant impact on exercise capacity, HRQL, and survival.<sup>26</sup> Previous studies have shown that the incidence of heart failure in patients with COPD worsened their health status.<sup>24,27</sup> These previous reports strengthen the importance of peak O<sub>2</sub>P measurement in patients with COPD.

Acute exacerbation of COPD leads to significant morbidity and mortality. Prior exacerbation history is a well-established predictor of future exacerbation.<sup>1</sup> In the current study, patients with impaired peak O<sub>2</sub>P had more COPD-related hospitalizations during 1-year follow-up. To our knowledge, peak O<sub>2</sub>P is a novel predictor of exacerbation. This study established the role of peak O<sub>2</sub>P in patients with COPD. Patients with impaired peak O<sub>2</sub>P had more susceptibility to severe exacerbation, thus we should pay more attention to reduce risks such as adjustment of inhaled bronchodilators or corticosteroids. A larger study is needed to validate the role of peak O<sub>2</sub>P in exacerbation risk.

In the current study, the echocardiographic parameters and cardiovascular comorbidities except hypertension revealed that no significant differences could be detected between the two groups. However, the gold standard of stroke volume and pulmonary artery pressure measurement requires invasive instruments such as a pulmonary artery catheter. In addition, heart failure is a clinical diagnosis and there is no diagnostic tool. In Group 2 patients, the peak O<sub>2</sub>P may imply the overall conditions of worse hyperinflation, heart failure, and pulmonary hypertension.

The cardiopulmonary disorders could result in more COPD-related hospitalizations, worse exercise capacity, HRQL, and circulatory and ventilator parameters.

## Limitations Of The Study

There are some limitations in this study. First, we did not measure any lung volume, such as total lung volume, residual volume, etc. in these patients. The hyperinflation could not be shown in the current study. Second, we did not use right heart catheterization in these patients, and the degree of pulmonary hypertension was unavailable. Third, peak O<sub>2</sub>P indicates SV according to the Fick equation; however, we did not measure the arterial oxygen saturation and mixed venous oxygen saturation, hence the actual oxygen extraction value was unknown. Moreover, a previous study demonstrated that oxygen extraction is constant near peak exercise.<sup>8</sup> Therefore, the peak O<sub>2</sub>P could be a useful parameter of SV near peak exercise. Further studies are required to verify the impact of O<sub>2</sub>P on mortality, and long-term follow-up of these patients is necessary. Finally, the patients with impaired O<sub>2</sub>P had poor exercise capacity, HRQL, and more COPD-related hospitalizations. The effect of pulmonary rehabilitation on these patients should be verified.

## Conclusions

To the best of our knowledge, this is the first study that comprehensively demonstrated the impact of peak O<sub>2</sub>P on patients with COPD. Impaired peak O<sub>2</sub>P was shown to be associated with poor exercise capacity, circulatory function, ventilatory function, HRQL, and COPD-related hospitalizations. The AT and FEV1 showed a significant association with the peak O<sub>2</sub>P. Additionally, peak O<sub>2</sub>P is an important parameter in COPD, and could be an indicative parameter of the overall condition of lung hyperinflation, pulmonary hypertension, and heart failure comorbidity.

## Acknowledgements

This study was supported by grants from the Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation (TCRD-TPE-104-33 and TCRD-TPE-108-RT-4).

## Disclosure

The authors have no conflicts of interest in this work.

## References

1. Singh D, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. *Eur Respir J*. 2019;53(5):1900164. doi:10.1183/13993003.00164-2019
2. Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. *Annu Rev Pathol*. 2009;4:435–459. doi:10.1146/annurev.pathol.4.110807.092145
3. Alter P, Watz H, Kahnert K, et al. Airway obstruction and lung hyperinflation in COPD are linked to an impaired left ventricular diastolic filling. *Respir Med*. 2018;137:14–22. doi:10.1016/j.rmed.2018.02.011
4. Blanco I, Piccari L, Barbera JA. Pulmonary vasculature in COPD: the silent component. *Respirology*. 2016;21(6):984–994. doi:10.1111/resp.12772
5. Mezzani A. Cardiopulmonary exercise testing: basics of methodology and measurements. *Ann Am Thorac Soc*. 2017;14(Supplement\_1):S3–S11. doi:10.1513/AnnalsATS.201612-997FR
6. Murata M, Adachi H, Oshima S, Kurabayashi M. Influence of stroke volume and exercise tolerance on peak oxygen pulse in patients with and without beta-adrenergic receptor blockers in patients with heart disease. *J Cardiol*. 2017;69(1):176–181. doi:10.1016/j.jjcc.2016.02.017
7. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. *Eur Respir J*. 2005;26(2):319–338. doi:10.1183/09031936.05.00034805
8. Stringer WW, Hansen JE, Wasserman K. Cardiac output estimated noninvasively from oxygen uptake during exercise. *J Appl Physiol* (1985). 1997;82(3):908–912. doi:10.1152/jappl.1997.82.3.908
9. Borg GA. Psychophysical bases of perceived exertion. *Med Sci Sports Exerc*. 1982;14(5):377–381. doi:10.1249/00005768-19820500-00012
10. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. *Am Rev Respir Dis*. 1992;145(6):1321–1327. doi:10.1164/ajrccm/145.6.1321
11. Thirapatarapong W, Armstrong HF, Bartels MN. Comparing cardiopulmonary exercise testing in severe COPD patients with and without pulmonary hypertension. *Heart Lung Circ*. 2014;23(9):833–840. doi:10.1016/j.hlc.2013.12.015
12. Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. *Lancet Respir Med*. 2015;3(8):631–639. doi:10.1016/S2213-2660(15)00241-6
13. Vassaux C, Torre-Bouscoulet L, Zeineldine S, et al. Effects of hyperinflation on the oxygen pulse as a marker of cardiac performance in COPD. *Eur Respir J*. 2008;32(5):1275–1282. doi:10.1183/09031936.00151707
14. Lammi MR, Ciccolella D, Marchetti N, Kohler M, Criner GJ. Increased oxygen pulse after lung volume reduction surgery is associated with reduced dynamic hyperinflation. *Eur Respir J*. 2012;40(4):837–843. doi:10.1183/09031936.00169311
15. Come CE, Divo MJ, Estépar RS, et al. Lung deflation and oxygen pulse in COPD: results from the NETT randomized trial. *Respir Med*. 2012;106(1):109–119. doi:10.1016/j.rmed.2011.07.012
16. Paolillo S, Agostoni P. Prognostic role of cardiopulmonary exercise testing in clinical practice. *Ann Am Thorac Soc*. 2017;14(Supplement\_1):S53–S58. doi:10.1513/AnnalsATS.201610-818FR
17. Hawkins NM, Virani S, Ceconi C. Heart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health services. *Eur Heart J*. 2013;34(36):2795–2803. doi:10.1093/eurheartj/eh1192
18. Wasserman K, Beaver WL, Whipp BJ. Gas exchange theory and the lactic acidosis (anaerobic) threshold. *Circulation*. 1990;81(1 Suppl):II14–II30.



19. Gitt AK, Wasserman K, Kilkowski C, et al. Exercise anaerobic threshold and ventilatory efficiency identify heart failure patients for high risk of early death. *Circulation*. 2002;106(24):3079–3084. doi:10.1161/01.CIR.0000041428.99427.06
20. Park J, Lee CH, Lee YJ, et al. Longitudinal changes in lung hyperinflation in COPD. *Int J Chron Obstruct Pulmon Dis*. 2017;12:501–508. doi:10.2147/COPD.S122909
21. Zhao L, Peng L, Wu B, Bu X, Wang C. Effects of dynamic hyperinflation on exercise capacity and quality of life in stable COPD patients. *Clin Respir J*. 2016;10(5):579–588. doi:10.1111/crj.12260
22. Arbex FF, Alencar MC, Souza A, et al. Exercise ventilation in COPD: influence of systolic heart failure. *COPD*. 2016;13(6):693–699. doi:10.1080/15412555.2016.1174985
23. Ingle L, Sloan R, Carroll S, Goode K, Cleland JG, Clark AL. Abnormalities of the ventilatory equivalent for carbon dioxide in patients with chronic heart failure. *Pulm Med*. 2012;2012:589164. doi:10.1155/2012/589164
24. Urf M, Van den Berg JW, Uil SM, Chavannes NH, Damoiseaux RA. Depression and heart failure associated with clinical COPD questionnaire outcome in primary care COPD patients: a cross-sectional study. *NPJ Prim Care Respir Med*. 2014;24:14066. doi:10.1038/nppcr.2014.66
25. Mirdamadi M, Rahimi B, Safavi E, Abtahi H, Peiman S. Correlation of cardiopulmonary exercise testing parameters with quality of life in stable COPD patients. *J Thorac Dis*. 2016;8(8):2138–2145. doi:10.21037/jtd.2016.07.07
26. Vanfleteren MJ, Koopman M, Spruit MA, et al. Effectiveness of pulmonary rehabilitation in patients with chronic obstructive pulmonary disease with different degrees of static lung hyperinflation. *Arch Phys Med Rehabil*. 2018;99(11):2279–2286.e3. doi:10.1016/j.apmr.2018.05.011
27. Sundh J, Ställberg B, Lisspers K, Kämpe M, Janson C, Montgomery S. Comparison of the COPD Assessment Test (CAT) and the Clinical COPD Questionnaire (CCQ) in a clinical population. *COPD*. 2016;13(1):57–65. doi:10.3109/15412555.2015.1043426

## International Journal of Chronic Obstructive Pulmonary Disease

Dovepress

### Publish your work in this journal

The International Journal of COPD is an international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus is given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management

protocols. This journal is indexed on PubMed Central, MedLine and CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal>